Comparative Pharmacology
Head-to-head clinical analysis: NESACAINE versus NESACAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESACAINE versus NESACAINE MPF.
NESACAINE vs NESACAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nesacaine (chloroprocaine) is an ester-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
Injectable local anesthetic: 1% or 2% solution, maximum dose 7 mg/kg (not to exceed 500 mg) with epinephrine, 4.5 mg/kg (not to exceed 300 mg) without epinephrine. Administer by infiltration or nerve block; may repeat at 30-minute intervals.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
None Documented
None Documented
Terminal half-life: 40-60 minutes (rapidly metabolized by plasma pseudocholinesterase); clinical context: prolonged with hepatic dysfunction or atypical pseudocholinesterase
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Renal: 90-95% as unchanged drug and metabolites (predominantly 4-hydroxypropycaine); biliary/fecal: <5%
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Category C
Category C
Local Anesthetic
Local Anesthetic